Eye On ROI: Will More Indian Firms Re-Calibrate US Market Presence?

Could more Indian firms consider re-aligning their US business amid heightened pricing and compliance pressures that have cast a shadow on the long-term viability of the generics segment? A cross section of experts including a senior executive at McKinsey & Co share their views on what to expect.

Indian Firms May Temper US business • Source: Shutterstock

Indian pharmaceutical firms are seen re-calibrating their strategy for the US market in an increasingly competitive environment aggravated by price erosion and the growing cost of compliance.

While it’s not as if some sharp exodus is in the offing, but there’s a shift away, at least at...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip